Syncona Shs GBP (SYNC) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 483.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: -31.72%
• EPS Growth: -404.64%
• Country: UK
• Employees: 1,050
• Sector: Financial
• Sector Strength: 70
• Industry: Asset Management
• EPS (TTM): -0.04
• Shares Outstanding: 608,193,050
• 10 Day Avg. Volume: 510,558
• 30 Day Avg. Volume: 483,919
• PEG Ratio: <0.01
• Price to Book (P/B): 0.51
• Price to Sales (P/S): -7.82
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £189.00
• Price Target Upside: 101.28% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: 96.00p ▲(2.24% Upside)

The score is held back primarily by highly volatile and recently weak financial performance and negative technical momentum. Offsetting this are a conservatively positioned balance sheet (no debt) and positive corporate actions aimed at returning capital and improving shareholder value, but losses (negative P/E) keep the overall risk/quality profile mid-range.

Positive Factors

Strong Balance Sheet

A strong balance sheet with zero debt enhances financial stability and provides flexibility for future investments and growth opportunities.

Improved Cash Flow

Improved cash flow indicates efficient cash management, supporting operational needs and strategic investments, enhancing long-term sustainability.

Strategic Share Buyback

The share buyback program reflects strategic capital management, potentially enhancing shareholder value and signaling confidence in the company's prospects.

Negative Factors

Revenue Volatility

Revenue volatility poses challenges for consistent profitability, impacting long-term financial planning and investor confidence.

Negative Valuation Metrics

Negative valuation metrics suggest potential overvaluation concerns, which could affect investor sentiment and capital raising capabilities.

Market Challenges

Bearish market trends indicate potential challenges in stock performance, affecting investor confidence and market positioning.

Syncona Shs GBP Business Overview & Revenue Model

Company Description

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.

How the Company Makes Money

Syncona makes money by investing in and managing a portfolio of life sciences companies. The company's revenue model primarily involves generating returns from its investments in these companies, either through exits such as public offerings or acquisitions, or through the appreciation of its equity stakes. Syncona often takes a long-term approach, providing capital and strategic guidance to help these businesses grow and reach significant value milestones. Key revenue streams include realized gains from the sale of investments, dividends from successful portfolio companies, and potential royalties or milestone payments from partnerships. The company's strategy is supported by its expertise in the life sciences sector and its commitment to building sustainable businesses that can achieve commercial success.

Syncona Shs GBP Financial Statement Overview

Summary

Balance sheet strength is a key positive (no debt and substantial equity), but the latest annual period saw a sharp deterioration with earnings turning deeply negative and multi-year profitability/cash flow remaining volatile, limiting overall quality and visibility.

Income Statement

Results are highly volatile, with revenue swinging from positive to negative and a sharp deterioration in the latest annual period (2025-03-31), where revenue and earnings turned deeply negative. Profitability is inconsistent across years (strong profit in 2021 and 2022, losses in 2020, 2023, and 2025), suggesting earnings are heavily driven by investment revaluations rather than steady operating performance. The main strength is that the company has demonstrated it can generate meaningful profits in better markets, but overall visibility and stability are weak.

Balance Sheet

The balance sheet is conservatively positioned with zero debt reported across all periods, which materially reduces financial risk. Equity remains sizeable (roughly £1.05–£1.31bn) and assets track closely to equity, indicating limited leverage. The key weakness is shareholder returns are inconsistent (negative return on equity in multiple years, including the latest), reflecting uneven profitability rather than balance-sheet stress.

Cash Flow

Cash generation is mixed: operating cash flow was strong in 2024 and improved further in 2025, but it was near-zero or negative in 2021 and 2023, highlighting variability in cash conversion. Free cash flow is also inconsistent (positive in 2020, 2022, 2024; negative in 2021 and 2023; and reported as zero in 2025), which reduces confidence in recurring cash generation. A positive is that in stronger years free cash flow kept pace with earnings, but cash flow stability remains the main concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-19.94M	-68.31M	30.75M	-39.79M	18.69M	78.54M
Gross Profit	-64.29M	-68.31M	14.10M	-51.91M	3.68M	78.54M
EBITDA	-128.47M	-143.16M	3.79M	0.00	-1.94M	0.00
Net Income	-143.16M	-143.16M	3.79M	-56.02M	8.84M	53.16M
Balance Sheet
Total Assets	1.06B	1.06B	1.25B	1.27B	1.33B	1.34B
Cash, Cash Equivalents and Short-Term Investments	1.11M	1.11M	261.00K	11.00K	276.00K	14.00K
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	11.79M	11.79M	12.22M	13.76M	23.55M	38.12M
Stockholders Equity	1.05B	1.05B	1.24B	1.25B	1.31B	1.30B
Cash Flow
Free Cash Flow	19.76M	0.00	20.47M	-265.00K	262.00K	-3.00K
Operating Cash Flow	43.91M	43.91M	20.47M	-265.00K	262.00K	-3.00K
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	-43.06M	-43.06M	-20.22M	0.00	0.00	0.00

Syncona Shs GBP Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 93.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SYNC, the sentiment is Neutral. The current price of 93.9 is below the 20-day moving average (MA) of 98.75, below the 50-day MA of 96.39, and below the 200-day MA of 94.82, indicating a neutral trend. The MACD of 0.73 indicates Positive momentum. The RSI at 51.05 is Neutral, neither overbought nor oversold. The STOCH value of 21.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:SYNC.

Syncona Shs GBP Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLDN	76 Outperform	£1.94B	10.58	6.14%	2.40%	64.34%	77.61%
Sector *	68 Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
MERC	67 Neutral	£117.30M	35.26	1.79%	3.29%	-9.37%	―
ASHM	65 Neutral	£1.56B	19.72	9.75%	9.91%	-28.89%	-12.14%
GROW	63 Neutral	£875.39M	8.13	8.92%	―	11.00%	―
SYNC	55 Neutral	―	-6.45	-12.49%	―	-31.72%	-404.64%
IPO	50 Neutral	£522.99M	-4.12	-14.23%	―	―	33.10%

Syncona Shs GBP Corporate Events

Syncona Ups Beacon Therapeutics Stake as Gene Therapy Group Raises $75m Series C

Syncona has committed $24.5 million to Beacon Therapeutics’ oversubscribed $75 million Series C financing, boosting the valuation of its holding in the ophthalmic gene therapy company and lifting the carrying value of the stake by £29.3 million, a 20% uplift since September 2025. The new funding round, led by Goldman Sachs Alternatives with participation from the Retinal Degeneration Fund and existing investors, will support completion and commercial preparation of Beacon’s lead gene therapy laru-zova for X-linked retinitis pigmentosa, as well as advance its broader retinal disease pipeline; on full drawdown, Syncona’s holding in Beacon will be valued at about $237.6 million with a 38.4% ownership stake, underscoring the strategic importance of Beacon in Syncona’s portfolio ahead of pivotal clinical data expected in the second half of 2026.

The most recent analyst rating on (GB:SYNC) stock is a Hold with a £96.00 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.

Syncona Limited Announces Total Voting Rights Update

Syncona Limited has announced that as of 28 November 2025, the total number of ordinary shares in issue is 672,549,420, with 64,356,396 shares held in treasury, which do not carry voting rights. Consequently, the total number of voting rights in the company is 608,193,024, a figure that shareholders can use to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:SYNC) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.

Syncona Limited to Issue New Shares Under Incentive Scheme

Syncona Limited announced the issuance of 334,788 new ordinary shares as part of its long-term incentive scheme, representing approximately 0.055% of its existing shares. These shares, which will be issued at a price of £0.996 per share, are subject to a one-year holding period before they can be sold or transferred. The shares are expected to be admitted to the Official List and begin trading on the London Stock Exchange on 20 November 2025, reflecting Syncona’s commitment to rewarding its stakeholders and aligning with its strategic growth initiatives.

The most recent analyst rating on (GB:SYNC) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.

Syncona Limited Reports Interim Results, Positions for Growth in Biotech Sector

Syncona Limited announced its interim results for the six months ending September 30, 2025, highlighting a mature portfolio poised to deliver value amid improving biotech market conditions. The company is funded to achieve eight key value inflection points over the next three years, with five expected in 2026, aiming to drive significant NAV growth and liquidity events. Syncona is also implementing refined proposals to maximize shareholder value, including returning £250 million from sales of mature private portfolio companies and establishing a new private fund to diversify funding sources.

The most recent analyst rating on (GB:SYNC) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.

Syncona Highlights Autolus Therapeutics’ Q3 2025 Financial Performance and Strategic Growth

Syncona Limited, a prominent life science investor, highlights the third-quarter 2025 financial results of its portfolio company, Autolus Therapeutics. Autolus, a biopharmaceutical firm specializing in next-generation T cell therapies, reported $21.1 million in net product revenue for AUCATZYL® and achieved its target of 60 authorized treatment centers. The company is expanding its clinical data and market presence, particularly in severe refractory systemic lupus erythematosus and pediatric acute lymphoblastic leukemia, while enhancing its leadership team to support growth. These developments are expected to bolster Autolus’ market position and offer promising prospects for stakeholders.

The most recent analyst rating on (GB:SYNC) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.

Syncona Unveils Strategic Update to Maximize Shareholder Value

Syncona Limited has announced a strategic update aimed at maximizing shareholder value and creating a sustainable structure for stakeholders. The company plans to return £250 million to shareholders from the sale of mature portfolio companies, with the board considering various methods for capital returns. The strategy includes a new investment objective focused on realizing value from mature assets and making selective new investments. The company will consult shareholders on new incentive arrangements and capital allocation policies, while also optimizing its cost base and exploring the establishment of a new private fund. The board emphasizes the importance of long-term capital appreciation and maintaining a pipeline of early-stage investments to support future growth.

The most recent analyst rating on (GB:SYNC) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Syncona Shs GBP stock, see the GB:SYNC Stock Forecast page.